Catalyst
Slingshot members are tracking this event:
Protalix (PLX) has completed a successful Type B Pre-BLA meeting with the FDA regarding the Accelerated Approval pathway for pegunigalsidase alfa (PRX‑102) for the treatment of Fabry disease
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PLX |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 18, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Bla Filing, Accelerated Pathway, Pegunigalsidase Alfa, Prx-102, Fabry Disease